Semantic Recognition Task (SRT) in Alzheimer Disease (SRT)

September 30, 2024 updated by: Jbid DURSUN UNCU, Istanbul University

A Sensitive Measurement Proposal in Alzheimer's Disease: Semantic Recognition Task

The goal of this study is to observe the outcomes of a semantic recognition task in Alzheimer Disease and discuss what this might add to clinical practice.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

In classical memory testing procedures, the outcomes of recognition task is related to hippocampal memory deficits knowing that the recognition task is not purely temporal lobe activity. The aim of this study is to propose a recognition task more specific to temporal lobe activity.

Study Type

Interventional

Enrollment (Estimated)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Turkey
    • İstanbul
      • Beşiktaş, İstanbul, Turkey, 34340
        • Recruiting
        • Jbid Dursun Uncu
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • to have biomarker analysis for Alzheimer disease (positive or negative).

Exclusion Criteria:

  • illiteracy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Semantic information in Alzheimer Disease
To observe the semantic information processing in early stages of Alzheimer Disease is the main aim of the study. A paper-pencil neuropsychological assessment battery will be used. For memory testing FCSRT (free and cued selective reminding test) will be used. The patients are going to be assessed while in clinical diagnosis routine.
Behavioral: Semantic Recognition Procedure
A semantic recognition task is going to be added to administrated FCSRT procedure after immediate and delayed recall phases.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Semantic Recognition Task
Time Frame: 1 day
The number of correct answers will be observed just after the short-term learning procedure and just after the delayed recall procedure among people with positive biomarker compared to those with negative biomarker to Alzheimer Disease.
1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Istanbul University

Investigators

  • Study Director: İ. Hakan Gürvit, Prof. MD., Istanbul University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 21, 2022

Primary Completion (Estimated)

September 20, 2025

Study Completion (Estimated)

December 26, 2027

Study Registration Dates

First Submitted

January 26, 2023

First Submitted That Met QC Criteria

February 2, 2023

First Posted (Actual)

February 3, 2023

Study Record Updates

Last Update Posted (Actual)

October 2, 2024

Last Update Submitted That Met QC Criteria

September 30, 2024

Last Verified

September 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • E-29624016-050.99-1484553

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe